Medicines Co. Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -4.200% | -14.974% | -8.144% | -24.245% | -35.137% | -34.743% | -33.143% |
| Opko Health Inc. | -1.600% | -3.158% | -5.155% | -15.332% | -15.612% | -39.704% | -66.300% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 1.110% | -0.552% | -0.552% | -7.692% | -8.163% | -39.189% | -19.643% |
Comments
News
Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter
Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Erasca (NASDAQ:ERAS), a developer of therapies for RAS/MAPK pathway-driven cancers, closed at $9.90, down 48% on Tuesday. Shares fell after the company disclosed a patient death from pneumonitis in
